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Although the prevalence rate is low 
there is a good chance an anesthesia 
clinician will experience a malignant 
hyperthermia crisis at least once in 
their career and they must be aware of 
how to handle the situation. That is 
why I picked this rare topic. I am in the 
Nurse Anesthesia program, and 
providing information about this crisis 
can spread awareness about a 
situation that could directly affect my 
colleagues’ or my own career.  
The condition was termed in 1960, 
by Denborough and Lovell who 
described the disorder in a family with 
this autosomal dominant mode of 
inheritance (Bandschapp & Girard, 
2012). Years later in the 1970’s 
mortality rates for the hyperthermia 
crisis were still over 80%, and after 
years of research the pathogenesis of 
the complication was discovered, 
along with the medical treatment in 
dantrolene (Bandschapp & Girard, 
2012).  
Currently, mortality rates have 
decreased to less than 5% because of 
the symptoms being immediately 
recognized and treated by anesthesia 
clinicians (Bandschapp & Girard, 
2012). Malignant hyperthermia is still a 
very dangerous state, yet very 
treatable under the proper clinician 
education.  
 
A crisis of malignant hyperthermia is a 
medical emergency, and must be 
treated immediately with a coordinated, 
multidisciplinary team response in order 
to give the patient the highest chance 
for a successful recovery (Dirksen, Van 
Wicklin, Mashman, Neiderer, & Merritt, 
2013).  Malignant hyperthermia is 
defined by Bandschapp & Girard 
(2012), as “a disturbance of the skeletal 
muscle calcium homeostasis, triggered 
by volatile anaesthetics and 
depolarizing muscle relaxants.” Once a 
vulnerable patient is exposed to one of 
these triggering agents, a pathologic 
hypermetabolic response ensues, and 
the patient has a rapid increase in 
oxygen consumption and expired 
carbon dioxide, hyperthermia, acidosis, 
muscle rigidity, and hyperkalemia 
(Bandschapp & Girard, 2012).  
The event of malignant hyperthermia 
is very rare, but can easily progress to 
a life-threatening situation (Cain, Riess, 
Gettrust, & Novalija, 2014). Many 
clinicians are unprepared to manage 
and treat the event because of its rarity 
and the use of low-frequency, high risk 
skill set (Cain, Riess, Gettrust, & 
Novalija, 2014). Dirksen, Van Wicklin, 
Mashman, Neiderer, & Merritt (2013), 
claim that malignant hyperthermia 
occurs in approximately 1:3,000-50,000 
procedures in which general 
anesthetics are used.  
    A 34 y.o. man was admitted to the 
hospital for a cholecystectomy. On 
preop assessment the CRNA found 
no previous surgeries and a family 
history of anesthetic complications, 
but the patient could not tell what 
these issues were. Surgery went well 
with removal of the gallbladder, 
successful anesthetic reversal, and 
no apparent complications. After 
surgery the patient was stable with 
HR, 75 bpm, BP, 127/82, RR, 16/min, 
O2sat, 100%, temp., 36.9 C. Upon 
admission to the PACU, patient’s HR 
increases to 91 bpm, and RR, 21/min, 
and the nurse gives the patient 3 mg 
of Morphine IVP for pain and 
increases his oxygen delivery to 4 L 
NC. The nurse then continues to see 
increase in HR, RR, BP, and temp. 
After giving the patient another 3mg 
of Morphine IVP, and increasing his 
oxygen to 5L NC, the nurse calls the 
CRNA and surgeon to report changes 
in patient’s condition. After this, the 
patient reports muscle rigidity of the 
trunk, displays ventricular ectopy, and 
vital signs are now as follows: HR: 
127 bpm, BP: 167/101 mm Hg, RR: 
31/min, O2sat: 89%, and body temp: 
39.5 C. The CRNA, now at bedside, 
quickly makes the diagnosis of 
malignant hyperthermia and 
administers 2.5mg/kg of dantrolene 
IVP and 2 mEq/kg of bicarbonate and 
reintubated the patient. A cooling 
blanket is then applied to the patient 
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Malignant Hyperthermia is a 
medical emergency, and although rare, 
every person involved in the OR team 
must be prepared to act quickly and 
accurately to give the patient the best 
chance for survival. The only testing for 
MH includes a muscle biopsy or 
molecular genetic testing, which are too 
invasive for a preoperative screen 
(Bandschapp & Girard, 2012). 
Therefore, a thorough surgical and 
medical history must be done on the 
patient to check for possible MH 
complications that have occurred in the 
family. Perioperative personnel, 
especially CRNAs, must be properly 
educated to quickly and appropriately 
recognize, treat, and manage a patient 
in a malignant hyperthermia crisis. 
Conclusion 
Once MH is suspected, all triggering agents should be discontinued including 
the anesthetic gas, and sedation should be changed to propofol (Bandschapp & 
Girard, 2012). Then help should be called, and a preplanned MH multidisciplinary 
team/plan should be activated and personnel should follow preset MH policies and 
guidelines (Dirksen, Van Wicklin, Mashman, Neiderer, & Merritt, 2013). The CRNA 
should then hyperventilate the patient with high fresh gas flow (>10 L/min or 1.0 
FiO2), and then treat the patient with 2.5mg/kg bolus of dantrolene (Bandschapp & 
Girard, 2012). 
  
Implications Pathophysiology and Significance 
and an ABG and labs are drawn that show: pH, 7.21; Pco2, 75 mmHg; 
Po2, 85 mmHg; potassium, 7.2 mEq/L. The patient is then given 10 
units of regular insulin IVP, followed by 50 ml of 50% dextrose in water 
IV, and 10 mg/kg of calcium chloride. The patient is then transferred to 
the ICU unit (Anderson-Pompa, Foster, Parker, Wilks & Cheek, 2009).  
    This patient displays the many signs and symptoms of the post 
operative emergency, malignant hypothermia (MH). This is a condition 
that develops rapidly and must be treated immediately. This genetic 
skeletal muscle disorder does not always happen immediately. In 
some cases like this example, the signs and symptoms can occur after 
surgery in the recovery period (Cain, Riess, Gettrust, & Novalija, 
2014). The condition results in the body developing into a 
hypermetabolic state with tachycardia, hyperpyrexia, muscle 
contractions, and changes in electrolyte and acid-base balances 
(Johns, Stoudt, Scholtis, & Gavel, 2012). More specific clinical signs of 
MH included: a rise in end-tidal CO2 and lactic acid production leading 
to a respiratory and metabolic acidosis, muscle spasm/rigidity, 
especially of the masseter muscle and truncal area, hyperthermia of 
above 39º C, myoglobinuria and eventually renal failure, 
hyperkalemia, tachycardia/tachypnea, and cardiac arrhythmias/arrests 
(Dirksen, Van Wicklin, Mashman, Neiderer, & Merritt, 2013). These 
symptoms must be recognized quickly and there must be an 
emergency care plan in place to treat patients displaying these 
symptoms.  
 
     The underlying pathophysiology behind malignant hyperthermia begins with 
the excitation-contraction coupling mechanism where “the muscle action 
potential is propagated along the sarcolemmal membrane into the transverse 
tubule, where the dihydropyridine receptors (DHP receptor) sense the action 
potential voltage change and open up” (Bandschapp & Girard, 2012). The 
opening of the DHP receptors then activates the ryanodine recepors to open, 
which allows calcium to be released from the Sarcoplasmic reticulum of the 
muscle cells and cause muscle contraction (Bandschapp & Girard, 2012). The 
muscle contraction then relaxes as calcium is actively pumped back into the 
sarcoplasmic reticulum by the ATP-dependent calcium pump (Revello, 2012). 
Patients that are susceptible to MH have an autosomal dominant disorder in 
which they have a defect in the ryanodine receptor type 1 (RYR1) gene (Dirksen, 
Van Wicklin, Mashman, Neiderer, & Merritt, 2013). By pairing this abnormal 
ryanodine receptor gene with the presence of a triggering agent like anesthetic 
gasses (halothane, isoflurane, sevoflurane, desflurane, or enflurane) either 
alone or in combination with a depolarizing muscle relaxant (succcinylcholine), 
an uncontrolled calcium release from the sarcoplasmic reticulum will result as an 
effect of the triggering agent causing the RYR1 to remain open (Dirksen, Van 
Wicklin, Mashman, Neiderer, & Merritt, 2013). This calcium starts the actin-
myosin troponin interaction which makes the muscle contract by shortening the 
muscle fibers (Dirksen, Van Wicklin, Mashman, Neiderer, & Merritt, 2013).  This 
uncontrolled calcium release overwhelms the compensatory mechanism 
(calcium pump) within the cell and cause a sustained state of muscle 
contraction, which causes the hypermetabolic MH response (Dirksen, Van 
Wicklin, Mashman, Neiderer, & Merritt, 2013). Early on the muscle cells attempt 
to restore homeostasis through aerobic and anaerobic metabolism, however it is 
overpowered by the excessive amount of calcium in the myoplasm, and reaches 
















     This process is significant in that it rapidly depletes adenosine triphosphate 
(ATP) and increases glucose metabolism, oxygen consumption, carbon dioxide 
production, and heat production; as well as increases lactate production and 
worsens acidosis (Revello, 2012). As ATP stores become exhausted, the 
plasma membrane integrity lessens causing rhabdomyolysis and the leakage of 
myoglobin, CK, and electrolytes like potassium, phosphate, and magnesium into 
the circulation (Revello, 2012). This damage can cause skeletal muscle damage, 
renal failure, and cardiac arrhythmias or arrest (Dirksen, Van Wicklin, Mashman, 
Neiderer, & Merritt, 2013). 
    Dantorlene is a specific ryanodine receptor 
antagonist, and inhibits the increased calcium 
release form the sarcoplasmic reticulum, which 
is why it is the primary drug to treat MH 
(Bandschapp & Girard, 2012). The 2.5mg/kg 
bolus can be repeated up to 4 times until the 
MH signs and acidosis subside, and in some 
cases may require more than 10mg/kg 
(Bandschapp & Girard, 2012). The patient then 
must be packed in ice to attempt to keep the 
 
Implications must be taken especially by 
CRNA’s to monitor and be prepared for 
a MH crisis. Although a classic sign of 
MH is pyrexia, an increase in 
temperature usually occurs later than 
other signs (Bandschapp & Girard, 
2012). One of the first signs of MH is the 
continual occurrence of increased 
carbon dioxide despite increases in 
minute ventilation (Bandschapp & 
Girard, 2012). If this is noticed along with 
tachycardia, muscle rigidity, possible 
hyperthermia, diffuse perspiration, 
acidosis, and hyperkalemia, the CRNA 
or Anesthesiologist must be clued to the 
diagnosis of MH, and act immediately. 
patient’s temperature below 38.5 ºC. CRNAs must also regularly draw ABGs, and 
blood and urine labs, to check acid-base status, electrolytes, coagulation profile, 
creatinine, CK, and myoglobin (Bandschapp & Girard, 2012). If acidosis worsens or 
serum potassium climbs, an additional bolus of dantrolene should be given 
(Bandschapp & Girard, 2012).  
 
  CRNAs must also be attentive and 
monitor and treat other conditions 
caused by MH, like disseminated 
intravascular coagulation, kidney 
damage form the myoglobin in the blood, 
and rhabdomyolysis associated with 
electrolyte imbalances (Bandschapp & 
Girard, 2012). They may need to give 
fluids and diuretics to help clear 
myoglobin in the kidneys, or correct 
electrolyte imbalances, especially 
hyperkalemia. Once the condition is 
under control the patient needs to be 
transported to the intensive care unit for 
36-48 hours to monitor for possible 
reoccurring symptoms, and 1 mg/kg of 
dantrolene should be continued every 4-
8 hours as indicated by lab values and 
clinical parameters (Bandschapp & 
Girard, 2012).  
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